5 questions about NIH licenses to patents on Production of Attenuated Respiratory Syncytial Virus Vaccines

The NIH has a notice for comments on proposed licenses of several patents relating to the “Production of Attenuated Respiratory Syncytial Virus Vaccines”. See: https://federalregister.gov/a/2016-03486

We asked Peter Soukas, a Senior Technology Licensing Specialist in the Technology Transfer and Intellectual Property Office, at the National Institute of Allergy and Infectious Diseases (NIAID), these questions:

  1. What provisions exist in the license to protect US residents against excessive or unreasonable pricing?
  2. What provisions exist in the license to ensure access in developing countries?
  3. What are the royalty arrangements?
  4. How much money did the government spend on these inventions?
  5. How much do you reckon the company receiving the license will have to spend on further development?
Uncategorized